{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-067432","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.046144+00:00","generated_at":"2026-06-04T19:45:08.330575+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"UroGen Pharma FY2023: JELMYTO revenue $82.7M (+28% YoY), net loss narrows, UGN-102 NDA on track","bullets":["Full year JELMYTO net revenue $82.7M, up ~28% YoY from $64.4M; Q4 revenue $23.5M (+30% YoY).","Net loss narrowed to $102.2M ($3.55/share) for FY2023 from $109.8M ($4.81/share) in 2022.","Rolling NDA for UGN-102 initiated Jan 2024; completion target Sep 2024, potential FDA decision Q1 2025.","Licensed next-gen mitomycin formulations (UGN-103/104) from medac with IP protection until Dec 2041.","Restructured Pharmakon loan: lower interest rate, deferred payback, up to $100M additional credit facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-067432","json":"https://secwatch.observer/filing/0001193125-24-067432.json","markdown":"https://secwatch.observer/filing/0001193125-24-067432.md","text":"https://secwatch.observer/filing/0001193125-24-067432.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524067432/0001193125-24-067432-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524067432/d675566d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:45:08.330575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6acd33b72d8005b7d7d0a11544398670d249e248","claim":"UroGen Pharma Ltd. reported the fourth quarter of 2023 results: revenue $23.5 million.","evidence_excerpt":"UroGen reported JELMYTO net product revenues of $23.5 million in the fourth quarter of 2023, compared to $18.1 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524067432/0001193125-24-067432-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Revenue","value":"$23.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d68103f1fee9537c13428c0890d788e1bb5497b1","claim":"UroGen Pharma Ltd. reported the full year 2023 results: revenue $82.7 million.","evidence_excerpt":"Net JELMYTO product revenue for the full year 2023 was $82.7 million, compared to $64.4 million in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312524067432/0001193125-24-067432-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2023"},{"label":"Revenue","value":"$82.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}